Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by MaiwaldDr Gisela Grabow of Maiwald explains the importance of a comprehensive approach to the revision of pharmaceutical legislation that considers the relationship with IP rights and the Action Plan on IP -
Sponsored by Bird & BirdChris de Mauny of Bird & Bird discusses the current and future importance of sufficiency in light of recent UK case law
-
Sponsored by Lifang & PartnersYan Zhang and Lin Mu of Lifang & Partners discuss a Supreme People’s Court case that establishes the timeframe for damages awarded to trademark owners
-
Sponsored by Gün and PartnersAysel Korkmaz Yatkin and Aysu Eryaşar of Gun and Partners evaluate the position of Turkey’s IP courts in a case focusing on preliminary injunction assessments
-
Sponsored by Liu, Shen & AssociatesXiaoming Zhang and Haitao Li of Liu Shen & Associates describe how two cutting-edge technologies, 5G and artificial intelligence, are empowering each other
-
Sponsored by FB RiceJeremy Dobbin of FB Rice summarises the key changes implemented by the Design Amendment (Advisory Council on Intellectual Property Response) Act 2021 and advises when they take effect
